Alnylam Pharmaceuticals I... (ALNY)
NASDAQ: ALNY
· Real-Time Price · USD
265.69
-1.17 (-0.44%)
At close: May 14, 2025, 3:05 PM
Alnylam Pharmaceuticals Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2018 |
|---|---|---|---|---|---|---|
| GIVLAARI Revenue | 255.87M | 219.25M | 894.33M | 662.14M | 361.52M | 12.54M |
| GIVLAARI Revenue Growth | +16.70% | -75.48% | +35.07% | +83.15% | +2784.08% | n/a |
| Product Revenue | 1.65B | 1.24B | n/a | n/a | n/a | n/a |
| Product Revenue Growth | +32.60% | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 239.95M | 295.34M | 220.99M | 248.4M | 210.8M | 198.12M | 199.18M | 214.69M | 183.66M | 210.34M | 235.86M | 169.98M | 154.47M | 186.38M | 142.07M | 145.32M | 146.86M | 166.29M | 167.47M | 127.9M | 126.76M | 156.28M | 120.35M | 112.77M | 89.61M | 108.69M | 116.55M | 84.68M | 72.45M | 67.45M | 47.64M | 45.78M | 38.49M | 27.88M | 22.39M | 17.99M | 21.1M | 17.23M | 16.04M | 14.62M | 12.72M |
| Selling, General, and Administrative Revenue Growth | -18.75% | +33.64% | -11.03% | +17.84% | +6.40% | -0.53% | -7.23% | +16.90% | -12.69% | -10.82% | +38.75% | +10.04% | -17.12% | +31.19% | -2.24% | -1.05% | -11.69% | -0.71% | +30.94% | +0.90% | -18.89% | +29.85% | +6.72% | +25.85% | -17.55% | -6.74% | +37.63% | +16.88% | +7.40% | +41.58% | +4.07% | +18.95% | +38.07% | +24.50% | +24.48% | -14.75% | +22.48% | +7.43% | +9.67% | +14.92% | n/a |
| Research and Development Revenue | 265.12M | 300.17M | 270.93M | 294.14M | 261M | 272.14M | 253.18M | 248.53M | 230.57M | 262.04M | 245.37M | 205.71M | 169.89M | 229.05M | 194.57M | 182.63M | 185.9M | 168.47M | 161.78M | 155M | 169.57M | 201.3M | 160.8M | 163.89M | 129.13M | 131.04M | 139.94M | 137.58M | 96.86M | 117.77M | 95.25M | 90.63M | 86.98M | 105.01M | 97.94M | 83.17M | 96.27M | 82.83M | 68.62M | 67.01M | 58.03M |
| Research and Development Revenue Growth | -11.68% | +10.79% | -7.89% | +12.70% | -4.10% | +7.49% | +1.87% | +7.79% | -12.01% | +6.79% | +19.28% | +21.08% | -25.83% | +17.72% | +6.54% | -1.76% | +10.35% | +4.13% | +4.38% | -8.60% | -15.76% | +25.19% | -1.89% | +26.92% | -1.46% | -6.37% | +1.72% | +42.05% | -17.76% | +23.64% | +5.10% | +4.19% | -17.17% | +7.22% | +17.75% | -13.61% | +16.22% | +20.72% | +2.40% | +15.46% | n/a |